Clinical Trial Update: Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial of intravitreal REGN2176-3 for neovascular age-related macular degeneration was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• REGN2176-3

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2020-10-26